 Stealth BioTherapeutics Corp NASDAQ: MITO has submitted an elamipretide marketing application to the FDA for Barth syndrome. The submission is based on results from the SPIBA-001 Phase 3 Retrospective Natural History Control Trial, which compared data from the TAZPOWER Phase 23 trials open-label portion to match natural history controls. 